Fluoroquinolones and Anaerobes

The usefulness of fluoroquinolones for the treatment of mixed aerobic and anaerobic infections has been investigated since these agents started being used in clinical practice. Newer compounds have increased in vitro activity against anaerobes, but clinically relevant susceptibility breakpoints for...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2006-06, Vol.42 (11), p.1598-1607
Main Authors: Stein, Gary E., Goldstein, Ellie J. C.
Format: Article
Language:English
Subjects:
Agents
Anaerobic bacteria
Animal bites
Anti-Bacterial Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacteria
Bacteria, Anaerobic - drug effects
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Bacteroides
Bacteroides fragilis
Biological and medical sciences
Clostridium
Diarrhea
Fluoroquinolones
Fluoroquinolones - pharmacology
Humans
Infections
Infectious diseases
Medical sciences
Pathogens
Peptostreptococcus
Pharmacology. Drug treatments
Quinolones
Rates
Reviews of Anti-Infective Agents
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The usefulness of fluoroquinolones for the treatment of mixed aerobic and anaerobic infections has been investigated since these agents started being used in clinical practice. Newer compounds have increased in vitro activity against anaerobes, but clinically relevant susceptibility breakpoints for these bacteria have not been established. Pharmacodynamic analyses and corroboration by new data from clinical trials have enhanced our knowledge concerning the use of fluoroquinolones to treat selective anaerobic pathogens. These studies suggest that newer agents could be useful in the treatment of several types of mixed aerobic and anaerobic infections, including skin and soft-tissue, intra-abdominal, and respiratory infections. The major concerns with expanding the use of fluoroquinolones to treat anaerobic infections have been reports of increasing resistance in Bacteroides group isolates and the impact of these antibiotics on the incidence of Clostridium difficile-associated disease.
ISSN:1058-4838
1537-6591
DOI:10.1086/503907